PRNewsWire
10 Sept 2026, 23:20 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Beam Therapeutics' BEAM-302 trial for AATD showed transient Grade 1 ALT and/or AST elevations in patients. — Liver enzyme elevations in clinical trials are potential safety red flags that can delay FDA approval or limit a drug's commercial viability.
-0.60Pomerantz LLP is investigating Beam Therapeutics for potential securities fraud or unlawful business practices following the clinical data release. — The threat of a class-action lawsuit creates legal uncertainty and potential financial liability for the company.
-0.40Beam Therapeutics' stock price dropped 9.54% to $26.83 on September 8, 2026, following the release of updated clinical data. — This confirms immediate negative market sentiment and price discovery already occurring due to the trial results.
-0.20Which stocks this story touches
Continue reading
5 related stories
Search tags
A class action lawsuit has been filed against the company.
The company is facing a securities fraud investigation by Pomerantz LLP following a stock price drop and concerns over clinical trial data.
The company is the subject of an investigation by Pomerantz LLP on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
58m ago
